Review summary
Teaching objective: Primary care, coordinated with a multiple sclerosis neurologist, for a 44-year-old professor and public speaker who walks with a cane and has multiple sclerosis diagnosed elsewhere: confirming and classifying the disease with MRI of the brain and spine under the 2017 McDonald criteria and the 2021 MAGNIMS-CMSC-NAIMS consensus, choosing a disease-modifying therapy by course and risk under the AAN 2018 guideline, the screening and vaccination it needs before the first dose (hepatitis B serology, immunoglobulins, liver tests, blood counts, varicella and measles immunity, tuberculosis, inactivated vaccines at least two weeks ahead), its monitoring afterwards, a re-baseline MRI, recognizing relapse and pseudo-relapse, symptom care for spasticity, bladder, fatigue and heat sensitivity, mobility equipment and fall prevention, a workplace accommodation that discloses only what she chooses, bone health, mood screening, and preventive care, respecting her wish to keep her diagnosis private.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| February 21, 1936 | Born in Houston, Texas. | CLM-0001 |
| 1959 | Law degree from Boston University. | CLM-0001 |
| 1966 | Elected to the Texas Senate. | CLM-0002 |
| November 1972 | Elected to the U.S. House of Representatives. | CLM-0002 |
| 1974 | House Judiciary Committee impeachment hearings. | CLM-0002 |
| 1976 | Keynote address at the Democratic National Convention. | CLM-0003 |
| 1978 | Walking with a cane in her last House years, attributed at the time to a knee problem. | CLM-0005 |
| 1979 | Left the House; became a professor at the LBJ School of Public Affairs; multiple sclerosis diagnosed around this time, as later revealed. | CLM-0004, CLM-0006 |
| 1988 | Spoke from a wheelchair at the Democratic National Convention. | CLM-0007, CLM-0008 |
| 1992 | Convention keynote address from a wheelchair. | CLM-0007 |
| 1994 | Presidential Medal of Freedom. | CLM-0009 |
| January 17, 1996 | Died in Austin at 59. | CLM-0010 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Barbara Jordan was born on February 21, 1936, in Houston, Texas, the youngest of three daughters, and grew up in Houston's Fifth Ward. She graduated magna cum laude from Texas Southern University in 1956 and earned a law degree from Boston University in 1959. | confirmed | Jordan, Barbara Charline (Handbook of Texas Online) supports Barbara Charline Jordan supports HISTMED Master Roster v3 context |
| D | In 1966 she was elected to the Texas Senate, the first Black state senator since 1883. In 1972 she was elected to the U.S. House of Representatives from Houston, the first Black woman from a Southern state to serve in Congress. As a member of the House Judiciary Committee during the 1974 impeachment hearings she said, "My faith in the Constitution is whole, it is complete, it is total." | confirmed | Jordan, Barbara Charline (Handbook of Texas Online) supports JORDAN, Barbara Charline (Biographical Directory and Black Americans in Congress profile) supports Boyer EJ. Barbara Jordan, voice of conscience, dead at 59 (Los Angeles Times) supports |
| D | In 1976 she gave the keynote address at the Democratic National Convention, the first woman and the first African American to do so. Anchors her public speaking in the modern social history. |
confirmed | Jordan, Barbara Charline (Handbook of Texas Online) supports Boyer EJ. Barbara Jordan, voice of conscience, dead at 59 (Los Angeles Times) supports |
| D | She did not seek a fourth term and left the House in 1979, downplaying reports about her poor health and citing her "internal compass." She became the Lyndon Baines Johnson Public Service Professor at the LBJ School of Public Affairs of the University of Texas at Austin, where she taught until the early 1990s. Anchors the modern episode in her work as a professor and public speaker in Austin, and the reports of poor health at the time she left Congress. |
confirmed | Jordan, Barbara Charline (Handbook of Texas Online) supports JORDAN, Barbara Charline (Biographical Directory and Black Americans in Congress profile) supports Barbara Jordan, 1936-1996: A Powerful Voice for Justice and Social Change (People in America) supports |
| D | In her later years in the House she walked with a cane, which she attributed at the time to "a bum knee"; a disability-press account written after her death says this was the first adaptive equipment her multiple sclerosis required, and that she did not openly acknowledge the disease for years. The anchor for the modern episode, which begins about a year after she left the House, with a spastic gait and a cane. The account is a single posthumous article that reports her own public explanation at the time; it is graded probable. |
probable | Cooper-Dowda R. Barbara Jordan: Hiding in Plain Sight While Working for 'The Common Good' supports |
| D | It was later revealed that she had been diagnosed with multiple sclerosis around the time she left Congress. The year of the diagnosis is not stated in the obituaries and reference works consulted. Anchors the modern problem of multiple sclerosis diagnosed elsewhere before the index visit. Its timing is uncertain (see CLM-0008). |
probable | Barbara Jordan supports Barbara Jordan, 1936-1996: A Powerful Voice for Justice and Social Change (People in America) supports |
| D | She spoke from a wheelchair at the Democratic National Convention in 1988, and in 1992 she gave a second convention keynote address from a wheelchair, amid a lengthy battle with multiple sclerosis. History after the modern episode; used only as context for the mobility planning. |
confirmed | JORDAN, Barbara Charline (Biographical Directory and Black Americans in Congress profile) supports Barbara Jordan, 1936-1996: A Powerful Voice for Justice and Social Change (People in America) supports Lunardini CA. Jordan, Barbara (Encyclopedia of African-American Culture and History) supports |
| D | Accounts differ on when her multiple sclerosis became public. A broadcaster's profile says it was announced after she left Congress; a disability-press article says her doctors made it public only after she nearly drowned in her pool during physical therapy, which it dates to 1994 (the Texas State Historical Association dates the near-drowning to 1988 and does not link it to the disease); a reference work says her obituaries explained much she had kept private, confirming the multiple sclerosis. Her obituaries reported that she had battled multiple sclerosis for several years and moved about in a wheelchair or with a walker. Recorded as history; the modern episode does not depend on the date of disclosure, but respects her privacy about her health. |
disputed | Barbara Jordan, 1936-1996: A Powerful Voice for Justice and Social Change (People in America) supports Cooper-Dowda R. Barbara Jordan: Hiding in Plain Sight While Working for 'The Common Good' supports Jordan, Barbara Charline (Handbook of Texas Online) context Lunardini CA. Jordan, Barbara (Encyclopedia of African-American Culture and History) supports Boyer EJ. Barbara Jordan, voice of conscience, dead at 59 (Los Angeles Times) supports |
| D | She received the Presidential Medal of Freedom in 1994. | confirmed | Boyer EJ. Barbara Jordan, voice of conscience, dead at 59 (Los Angeles Times) supports |
| D | She died in Austin on January 17, 1996, at 59, of pneumonia as a complication of leukemia, and is buried in the Texas State Cemetery. History only, long after the modern episode; not used in it. |
confirmed | Boyer EJ. Barbara Jordan, voice of conscience, dead at 59 (Los Angeles Times) supports Jordan, Barbara Charline (Handbook of Texas Online) supports JORDAN, Barbara Charline (Biographical Directory and Black Americans in Congress profile) supports Barbara Charline Jordan supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spine | resolved | confirmed | active | CLM-0005, CLM-0006 |
| S | Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 2017 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosis | active | confirmed | both_with_link | CLM-0005, CLM-0006 |
| S | Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of falls | active | confirmed | active | CLM-0005 |
| S | Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residual | active | confirmed | active | |
| S | Vitamin D deficiency | active | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-03-02 | Leukocytes [#/volume] in Blood by Automated count | 6.4 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-03-02 | Lymphocytes [#/volume] in Blood by Automated count | 1.9 10*3/uL Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 2026-03-02 | Hemoglobin [Mass/volume] in Blood | 13.2 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-03-02 | Platelets [#/volume] in Blood by Automated count | 262 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-03-02 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 96 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-03-02 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 U/L Reference 10-35 U/L |
http://loinc.org · 1920-8 |
| S | 2026-03-02 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 72 U/L Reference 35-105 U/L |
http://loinc.org · 6768-6 |
| S | 2026-03-02 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 mg/dL Reference 0.2-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-03-02 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 mIU/L Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-03-02 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 520 pg/mL Reference 232-1245 pg/mL |
http://loinc.org · 2132-9 |
| S | 2026-03-02 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 17 ng/mL (low) Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-03-02 | IgG [Mass/volume] in Serum or Plasma | 1080 mg/dL Reference 700-1600 mg/dL |
http://loinc.org · 2465-3 |
| S | 2026-03-02 | IgM [Mass/volume] in Serum or Plasma | 110 mg/dL Reference 40-230 mg/dL |
http://loinc.org · 2472-9 |
| S | 2026-03-02 | IgA [Mass/volume] in Serum or Plasma | 210 mg/dL Reference 70-400 mg/dL |
http://loinc.org · 2458-8 |
| S | 2026-03-02 | JC virus Ab Index in Serum or Plasma by Immunoassay | 0.14 Reference Below 0.20 negative; 0.20 to 0.40 indeterminate; above 0.40 positive |
http://loinc.org · 100977-8 |
| S | 2026-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-06-29 | Leukocytes [#/volume] in Blood by Automated count | 5.9 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-06-29 | Lymphocytes [#/volume] in Blood by Automated count | 1.4 10*3/uL Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 2026-06-29 | Hemoglobin [Mass/volume] in Blood | 13.4 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-06-29 | Platelets [#/volume] in Blood by Automated count | 248 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-06-29 | CD19 cells [#/volume] in Blood | 3 /uL (low) Reference Expected to be depleted after an anti-CD20 therapy |
http://loinc.org · 8116-6 |
| S | 2026-06-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-06-29 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 ng/mL Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 2026-08-17 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4% Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes |
http://loinc.org · 4548-4 |
| S | 2026-08-17 | Cholesterol [Mass/volume] in Serum or Plasma | 186 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-08-17 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 110 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-08-17 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 56 mg/dL Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-08-17 | Triglyceride [Mass/volume] in Serum or Plasma | 98 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-10-26 | Leukocytes [#/volume] in Blood by Automated count | 6.1 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-10-26 | Lymphocytes [#/volume] in Blood by Automated count | 1.5 10*3/uL Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 2026-10-26 | Hemoglobin [Mass/volume] in Blood | 13.5 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-10-26 | Platelets [#/volume] in Blood by Automated count | 255 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-10-26 | IgG [Mass/volume] in Serum or Plasma | 1010 mg/dL Reference 700-1600 mg/dL |
http://loinc.org · 2465-3 |
| S | 2026-10-26 | IgM [Mass/volume] in Serum or Plasma | 72 mg/dL Reference 40-230 mg/dL |
http://loinc.org · 2472-9 |
| S | 2026-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 93 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-10-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 U/L Reference 10-35 U/L |
http://loinc.org · 1920-8 |
| S | 2026-08-17 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-03-02 | Body height | 173 cm | 8302-2 | S |
| 2026-03-02 | Body weight | 84 kg | 29463-7 | S |
| 2026-03-02 | Body mass index (BMI) [Ratio] | 28.1 kg/m2 | 39156-5 | S |
| 2026-03-02 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-03-02 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-03-02 | Heart rate | 76 /min | 8867-4 | S |
| 2026-03-02 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-02 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-03-16 | Body height | 173 cm | 8302-2 | S |
| 2026-03-16 | Body weight | 84.2 kg | 29463-7 | S |
| 2026-03-16 | Body mass index (BMI) [Ratio] | 28.1 kg/m2 | 39156-5 | S |
| 2026-03-16 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2026-03-16 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-03-16 | Heart rate | 74 /min | 8867-4 | S |
| 2026-03-16 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-16 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-04-20 | Body height | 173 cm | 8302-2 | S |
| 2026-04-20 | Body weight | 83.8 kg | 29463-7 | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 28 kg/m2 | 39156-5 | S |
| 2026-04-20 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-04-20 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-04-20 | Heart rate | 72 /min | 8867-4 | S |
| 2026-04-20 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-04-20 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-06-29 | Body height | 173 cm | 8302-2 | S |
| 2026-06-29 | Body weight | 83.5 kg | 29463-7 | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 27.9 kg/m2 | 39156-5 | S |
| 2026-06-29 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-06-29 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-06-29 | Heart rate | 74 /min | 8867-4 | S |
| 2026-06-29 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-06-29 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-10-26 | Body height | 173 cm | 8302-2 | S |
| 2026-10-26 | Body weight | 83.2 kg | 29463-7 | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 27.8 kg/m2 | 39156-5 | S |
| 2026-10-26 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-10-26 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-10-26 | Heart rate | 72 /min | 8867-4 | S |
| 2026-10-26 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-10-26 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-08-17 | Body height | 173 cm | 8302-2 | S |
| 2026-08-17 | Body weight | 83.4 kg | 29463-7 | S |
| 2026-08-17 | Body mass index (BMI) [Ratio] | 27.9 kg/m2 | 39156-5 | S |
| 2026-08-17 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-08-17 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-08-17 | Heart rate | 74 /min | 8867-4 | S |
| 2026-08-17 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-08-17 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Professor at a school of public affairs, teaching seminars on policy and ethics; a frequent public speaker; formerly a state senator and member of Congress
- S Lives in a single-story home in Austin; household details not recorded, at her request; drives to work
- S Keeps her diagnosis private; has told only those she chooses, and wants any letter to her employer to describe her needs, not her diagnosis
- S Tobacco: never. Alcohol: occasional, within low-risk limits. No drug use reported
- S Exercise: walks short distances; swimming was suggested to her before but she has not started
Functional status
- S Walks about 100 meters with a cane in her right hand before needing to rest (EDSS 6.0); timed 25-foot walk 11.2 seconds; climbs stairs with a rail; independent in self-care; drives; tires by mid-afternoon
Mental status
- S Alert, precise and articulate; mood steady; frustrated by fatigue; PHQ-9 score 6, mostly from fatigue and sleep items; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily
- S Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated
- S Baclofen 10 mg oral tablet, one tablet three times a day
- S Mirabegron 25 mg extended-release oral tablet, one tablet daily
- S Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center
Procedures and immunizations
Procedures
- S Bladder scan for post-void residual volume
- S MRI of the brain with and without gadolinium (3D T2-FLAIR, T2, and T1 before and after contrast)
- S MRI of the cervical and thoracic spine with and without gadolinium
- S Ocrelizumab 300 mg intravenous infusion (first half-dose) after premedication, with observation for at least one hour afterwards
- S Ocrelizumab 300 mg intravenous infusion (second half-dose) after premedication, with observation for at least one hour afterwards
- S MRI of the brain without gadolinium (re-baseline on therapy)
- S Dual-energy X-ray absorptiometry (DXA) of the lumbar spine and hip
- S Advance care planning conversation, about 20 minutes
- S Screening mammogram, both breasts
Immunizations
- S 2026-03-16: Pneumococcal conjugate vaccine PCV20
- S 2026-03-16: Recombinant zoster vaccine, dose 1 of 2
- S 2026-03-16: Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
- S 2026-03-16: Hepatitis B vaccine (HepB-CpG), dose 1 of 2
- S 2026-04-20: Hepatitis B vaccine (HepB-CpG), dose 2 of 2
- S 2026-04-20: Recombinant zoster vaccine, dose 2 of 2
- S 2026-10-26: Influenza vaccine, inactivated, this season
- S 2026-10-26: COVID-19 vaccine, mRNA, this season
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1978: Walking difficulty needing a cane in her last years in the House, attributed publicly at the time to a knee problem (CLM-0005)
- D 1979: Multiple sclerosis diagnosed around the time she left Congress, as later revealed; records of that evaluation are not available to this clinic (CLM-0006)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Diagnosis confirmed and classified, vaccines completed at least two weeks before therapy, and a disease-modifying therapy started within ten weeks | 2026-06-29 | completed | Primary progressive disease confirmed at two weeks; vaccines finished at five weeks; ocrelizumab started at nine weeks |
| No falls through eight months | 2026-10-26 | completed | No falls; one near-fall in the summer heat |
| 25-hydroxyvitamin D at least 30 ng/mL within four months | 2026-06-29 | completed | 34 ng/mL at four months |
| Up no more than once a night to pass urine within three months | 2026-06-29 | completed | Once a night or less on mirabegron |
| Keep her full teaching and speaking schedule with the accommodations she chooses | 2026-10-26 | completed | Full schedule kept; accessible rooms, seating and parking in place |
| No new or enlarging T2 lesions on the re-baseline MRI | 2026-10-26 | completed | No new or enlarging T2 lesions |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Confirm and classify the diagnosis: MRI of the brain and the cervical and thoracic spine with gadolinium to the MAGNIMS-CMSC-NAIMS protocol, read against the 2017 McDonald criteria; exclude mimics with vitamin B12, TSH and HIV; request the records of the original evaluation | completed | GL-MCDONALD-2017, GL-MAGNIMS-2021 |
| Neurology (multiple sclerosis) consultation to confirm and classify the disease and advise on disease-modifying therapy, its monitoring, vaccination, symptom care and MRI follow-up | completed | GL-AAN-DMT-2018, GL-MCDONALD-2017, GL-MAGNIMS-2021 |
| Screening before any disease-modifying therapy: hepatitis B surface antigen, core antibody and surface antibody; quantitative immunoglobulins; liver tests; blood count with lymphocytes; varicella and measles immunity; tuberculosis blood test; HIV and hepatitis C; JC virus antibody; and vaccines brought up to date, inactivated vaccines at least two weeks and live vaccines at least four weeks before the first dose | completed | GL-AAN-DMT-2018, GL-AAN-VAX-2019, GL-CDC-IMZ-2026 |
| Relapse and pseudo-relapse plan: new or worsening symptoms lasting more than 24 hours without fever or heat mean a same-day call; check for urinary infection and fever first, because infection and heat can bring back old symptoms; written card for her bag | completed | GL-AAN-DMT-2018, GL-NICE-MS-2022 |
| Mobility, spasticity and falls: physical therapy evaluation for gait, strengthening, stretching, balance and a home exercise program; review of walking aids, with forearm crutches or a rollator and a scooter for long distances when she wants them; home safety review; daily stretching | completed | GL-NICE-MS-2022, GL-CMID-2026 |
| Bladder: post-void residual today, timed voiding, fluids earlier in the day, less caffeine, pelvic floor exercises, and a medicine if urgency persists; urine check for any burning, fever or sudden worsening | completed | GL-NICE-MS-2022 |
| Fatigue and heat sensitivity: energy conservation and pacing with an occupational therapy review, teaching sessions placed in the morning where she chooses, cooling garments, air conditioning, cool drinks, and aerobic exercise such as pool exercise in cool water | completed | GL-NICE-MS-2022 |
| Work: a letter to her employer, with her consent, describing her functional needs (an accessible teaching room near an elevator, a chair and lectern for lectures, reserved parking near her building, and flexibility for medical appointments) without naming the diagnosis; she decides what to disclose | completed | GL-JAN-MS, GL-ADA |
| Bone health: vitamin D3 with a recheck, calcium from food, weight-bearing exercise, fall prevention, and bone density at the preventive visit because of reduced mobility and earlier steroid courses | completed | GL-CMID-2026, GL-NICE-MS-2022 |
| Mood and cognition: PHQ-9 at intake and every six months; ask about concentration and word-finding; counseling offered at any time | completed | GL-USPSTF-DEP-2023, GL-NICE-MS-2022, GL-CMID-2026 |
| On the consultant's advice: ocrelizumab 300 mg on day 1 and day 15 and then 600 mg every 6 months, after the vaccines and at least two weeks after the last inactivated dose, with premedication and observation; blood count and immunoglobulins before each dose; a re-baseline brain MRI three to six months after the first dose and then yearly; baclofen titrated to 10 mg three times a day; mirabegron with a blood pressure check at each visit | completed | GL-AAN-DMT-2018, GL-OCR-LABEL, GL-MAGNIMS-2021, GL-NICE-MS-2022 |
Planned encounters
- 2026-03-02 — Establishing primary care for multiple sclerosis diagnosed elsewhere: walking, spasticity, bladder, fatigue and heat sensitivity, work, bone health, mood, and the work-up and screening before any disease-modifying therapy (ENC-001)
- 2026-03-16 — Two-week review with MRI of the brain and spine and the neurology (multiple sclerosis) consultation; vaccines before therapy (ENC-002)
- 2026-04-20 — Five-week review: second vaccine doses, baclofen titration, physical therapy and readiness for the first infusion (ENC-003)
- 2026-06-29 — Four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood (ENC-004)
- 2026-08-17 — Periodic adult preventive visit (ENC-006)
- 2026-10-26 — Eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Preventive Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Neurology (multiple sclerosis) referral
- Neurology (multiple sclerosis) consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Neurology (multiple sclerosis) referral (XML)
- Neurology (multiple sclerosis) consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Jordan, Barbara Charline (Handbook of Texas Online) | Texas State Historical Association | biography |
| SRC-0002 | JORDAN, Barbara Charline (Biographical Directory and Black Americans in Congress profile) | U.S. House of Representatives, History, Art & Archives | government |
| SRC-0003 | Boyer EJ. Barbara Jordan, voice of conscience, dead at 59 (Los Angeles Times) | The Spokesman-Review | other |
| SRC-0004 | Barbara Jordan, 1936-1996: A Powerful Voice for Justice and Social Change (People in America) | Voice of America Learning English | other |
| SRC-0005 | Lunardini CA. Jordan, Barbara (Encyclopedia of African-American Culture and History) | Encyclopedia.com | biography |
| SRC-0006 | Cooper-Dowda R. Barbara Jordan: Hiding in Plain Sight While Working for 'The Common Good' | Ragged Edge Magazine | other |
| SRC-0007 | Barbara Jordan | Biography.com | biography |
| SRC-0008 | Barbara Charline Jordan | Texas State Cemetery | government |
| SRC-0009 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the McDonald classification as active primary progressive disease, the ocrelizumab choice and its screening, the vaccine timing, the re-baseline MRI without gadolinium, baclofen and mirabegron, and the decision to obtain bone density at 44. |
| provenance review | not_started | Recent-death rule: only what was reported in her life or in obituaries and reference works: the Texas State Historical Association, the House history, the Los Angeles Times obituary, a broadcaster's profile, an encyclopedia entry, a biography site, the State Cemetery and one disability-press article. The diagnosis year and the date of disclosure are uncertain and recorded as such. |
| safe messaging review | not_started | No mental health or substance claims are made; mood screening is synthetic and below the threshold for a safety assessment. Her death is recorded in one claim as history. Disability is described without pity language, and her privacy about the diagnosis is respected in the modern plan. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.